RICHARD L. MITCHELL, PH.D.

15920 177^th Avenue N.E.                                                                                   Home: (425) 402-6341

Woodinville, WA  98072                                                                                        Cell: (425) 922-1393

Email: richard.mitchell@verizon.net

PROFILE

Articulate professional with 22 years of broad scientific and business development leadership.  Demonstrated success in forging partnerships with pharmaceutical and biotechnology companies and establishing academic collaborations to solve unmet technical and medical needs.  Experienced educator and public speaker acting as a liaison between laboratory, business, and academic leaders. 

STRATEGIC PLANNING & IMPLEMENTATION

·        Technology licensing and company acquisitions

·        Marketing, competitive intelligence

·        Outstanding presentation skills

·        Establish collaborations, partnerships, consultancies

·        Technical, medical, scientific, and academic liaison with college teaching experience

·        Due diligence of delivery technology, therapeutics, and intellectual property acquisitions

·        Expertise in microbiology, molecular virology and oncology, molecular pharmacology, drug delivery, and drug discovery/development technologies applied to small molecule and peptide therapeutics

·        siRNA target selection  and siRNA delivery for viral infections, cancer, inflammation and immunomodulation targets

Nastech Pharmaceutical Company Inc. - Bothell, WA                                                           April 2006 - Present

SCIENTIFIC DIRECTOR, MARKETING AND BUSINESS DEVELOPMENT

(reporting to Chief Business Officer)

·        Provided strategic leadership to broaden core drug delivery capabilities, initiated acquisition efforts with several companies, progressing several to negotiated offers (~$25MM - $100MM)

·        Identified potential partners for proprietary therapeutics and managed relationships, drafting and providing preclinical and clinical data packages for prospective partners

·        Initiated drug delivery feasibility collaborations leading to partnerships including one entering the clinic in 2008

·        Completed drug delivery technology evaluations for over 100 companies and technologies covering multiple delivery routes including buccal, oral, pulmonary, nasal, transdermal, and parenteral/sustained-release injectables

o       Recommended four of these for significant partnership or acquisition activity

·        Technology acquisition efforts led to signed technology partnerships (e.g. formulation technology applied to sustained drug release and vaccine delivery)

·        Presented Nastech drug delivery technology and therapeutic drug programs to medical, scientific, and business audiences

o       Diabetes, obesity, osteoporosis, autism; siRNA therapeutic targets

o       Non-invasive peptide/protein drug delivery technologies, siRNA delivery

 Shoreline Community College - Shoreline, WA                                                 January – March 2006

(Reporting to CEO AND CFO)

·        Consulted with academic and industry thought leaders

·        Recommended corporate development strategy based on in-depth assessment of bacterial and viral infectious disease targets for proprietary electrochemical DNA sensor technology (Adnavance) and DNA-vaccine technology (Paracelsus)

·        Offered position of VP of Business Development by CEO and CFO following assignment

MDS Pharma Services (formerly Panlabs, Inc.) - Bothell, WA                                          1990 - 2005

·        Grew revenues >15-fold ($1.5 MM - $25 MM/yr) as Pharmacology Product Team Leader

·        Identified acquisition opportunities and provided technology due diligence for MDS Capital, MDS Pharma Services, and MDS Sciex

·        Identified and initiated acquisition efforts

o       Skeletech Inc. (preclinical CRO) ~$10 MM acquisition (2005)

o       Signature Biosciences (cellular dielectric spectroscopy) acquired by MDS Sciex 

·        Identified, negotiated, guided collaborations

o       Iconix Pharmaceuticals-MDS PS Chemoinformatics Database Collaboration (Collaboration Board Member)

o       BioSource – MDS PS Strategic Alliance; initiated, drafted & negotiated

o       Becton Dickenson (BD)-MDS Pharma Services Biomarker Alliance

·        Secured, managed pharma and biotech client relationships (e.g. managed/advised/technical liaison to Merck on preclinical testing strategies)

·        Led assay development team developing >400 pharmacology tests

·        Trained sales staff (approx. 3 face-to-face training sessions per year)

·        Delivered sales presentations (Asia, Europe, US) and provided technical sales support

·        Performed technology due diligence for MDS Capital Corp. (Amnis, Ambit, Aurora BioMed, Signature BioSciences, Specialty Laboratories, Nodality and others)

·        Conceived, designed & built key innovative IT systems & sales tools including:

o       Fully integrated client data delivery system and web interface

o       MDS Panlabs corporate website

o       MDS Panlabs sales team website

o       Automated sales quoting and tracking system (automated quoting and tracked performance vs. sales metrics and objectives)

o       Designed and developed automated sales aids (facilitated technical sales process)

·        NIH Phase I SBIR Grant:#1 R43 DA 09203-01 (Signal Transduction by Peripheral  Cannabinoid Receptors) – wrote pharmacology section of Phase I SBIR grant, performed pharmacology work (1994)

California Biotechnology Inc. (Scios Inc., Johnson & Johnson) – Mt. View, CA               1988 - 1990

·        Cloned and expressed genes encoding angiogenic growth factors (aFGF, bFGF, VEGF)

·        Supervised laboratory staff

·        Ph.D., Microbiology (virology/molecular biology focus) Univ. of Minnesota, Minneapolis, MN 1984

·        Ph.D. Program, Microbiology (immunology/virology focus) Univ. of Iowa, Iowa City, IA 1976-1978

·        B.A., Biology (Honors in the Major, College Honors) University of California, Santa  Cruz, CA 1976

·        Additional course: From Laboratory to Leadership, Washington Biotechnology and Biomedical Association (WBBA) (1999).

·        Additional course: Principles of Toxicokinetics and Pharmacokinetics.  University of Arizona. 2007.

Co-Inventor on Submitted Patent:  Mitchell, R., Mulligan, J., Castillo, G.  2005.  International Application WO2005069725  "Fluorescence-Based ADP Detection System"

Co-Inventor on US Patent: Tischer, E.G., J.A. Abraham, J.C. Fiddes, R.L. Mitchell.  1993.  U.S. Patent No. 5,219,739 for "DNA sequences encoding BVEGF120 and HVEGF121 and methods for the production of  bovine and human vascular endothelial cell growth factors, BVEGF120 and HVEGF121".

Co-Inventor on US Patent: Tischer, E.G., J.A. Abraham, J.C. Fiddes, R.L. Mitchell.  1992.  U.S. Patent No. 5,194,596 for "Production of vascular endothelial cell growth factor". 

·        CalBio Professional Recognition Award for Outstanding Achievement (1989)

·        Bacaner Research Award (for outstanding thesis) Minn. Med. Foundation,  Univ. of Minn. (1985)

·        NIH Individual Postdoctoral Fellowship Award, The Salk Institute, San Diego  (1984–1987)

·        USPHS Predoctoral Fellowship, Dept. of Microbiology, Univ. of Minn. (1978-1982)

·        Honors in Biology and College Honors, University of California, Santa Cruz  (1976)

Mitchell, R.L., Lai, Y., Mackie, K.P., and Thomsen, W.J.  Phase I Small Business Innovative Research Grant (NIH) #1 R43 DA 09203-01 Signal Transduction by Peripheral Cannabinoid Receptors, 1994.

·        Society for Neuroscience

·        The Obesity Society

·        American Society for Pharmacology and Experimental Therapeutics

·        American Association of Pharmaceutical Scientists

·        Licensing Executives Society

·        Photographic Society of America

·        Member, Institutional Animal Care and Use Committee (2006 – present)

·        Chair, MDS PS Scientific Advisory Committee 2004 – 2005

·        Chair, Shoreline Community College Biotechnology Advisory Committee 1997 - 2002

·        Member, Radiotherapeutic Build Team, MDS Nordion, developing Bexxar™ and  Zevalin™

·        Member, Iconix-MDS Collaboration Management Board (for chemoinformatic database)

·        Chairman, Panlab's Safety Committee, Vice-Chairman 1993 – 1994

Mitchell, R.L., Costantino, H.R., Sileno, A., Duffy, T., Brandt, G., Quay, S.C. 2008.  Intranasal Insulin: PK Profile Designed Specifically for Prandial Treatment of  Type 2 Diabetes.  Drug Development Research 69(3):143-152. (link)

Chiu, P.J.S., Marcoe, K.F., Bounds, S.E., Lin, C.-H., Feng, J.-J., Lin, A., Cheng, F.-C., Crumb, W.J., Mitchell, R. 2004.  Validation of a [³H]Astemizole Binding Assay in HEK293 Cells Expressing HERG K⁺ Channels. J. Pharmacol. Sci.. 95:311-319.

Herz, J.M., Thomsen, W.J., Mitchell, R., and Yarbrough, G.G. 1996. Receptors for Drugs. Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan  eds. vol. 13, Marcel Dekker, Inc., New York.

Hill, P., Lai, Y., Hnilo, J., Lin, C-C., Karla, M., Bounds, S., Middlemas, D., Herz, J., Mitchell, R.L. 1996. Cloning, expression, and comparison of the binding characteristics of the known human dopamine receptors. Advances in Neurology 69:41-52, Lippencott-Raven, Philadelphia.

Felder, C.C., Joyce, K.E., Briley, E.M., Mansouri, J., Mackie, K., Lai, Y., Mitchell, R.L., Ma, A.L. 1995. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 Receptors. Mol. Pharm. 48(3):443-450.

Mackie, K., Lai, Y., Westenbroek, R., Mitchell, R..  1995.  Cannabinoids activate an inwardly rectifying potassium conductance and inhibit non-L,N,P,T type voltage-dependent calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor.  J. Neuroscience 15(10):6552-6561.

Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C. and Abraham, J. A., 1991.  The human gene for vascular endothelial growth factor:  Multiple protein forms are encoded through alternative exon splicing.  J. Biol. Chem. 266:11947-11954.

Tischer, E., Gospodarowicz, D., Mitchell, R. L., Silva, M., Schilling, J., Lau, K., Crisp, T., Fiddes, J. C., and Abraham, J. A..  1989.  Vascular endothelial growth factor:  A new member of the platelet-derived growth factor gene family.  Biochem. Biophys. Res. Commun.  165:1198-1206.

Blam, S. B., Mitchell, R., Tischer, E., Rubin, J. S., Silva, Silver, M., S., Fiddes, J. C., Abraham, J., Aaronson, S..  1988.  Addition of growth hormone secretion signal to basic fibroblast growth factor results in cell transformation and secretion of aberrant forms of the protein.  Oncogene 3:129-136.

Neufeld, G., Mitchell, R., Ponte, P., and Gospodarowicz, D..  1988.  Expression of human basic fibroblast growth factor cDNA in baby hamster kidney-derived cells results in autonomous cell growth.  J. Cell. Biol.  106:1385-1394.

Ferrara, N., Schweigerer, L., Neufeld, G., Mitchell, R., and Gospodarowicz, D.  1987.  Pituitary follicular cells produce basic fibroblast growth factor.  Proc. Natl. Acad. Sci.  USA 84:5773-5777.

Neufeld, G., Ferrara, N., Schweigerer, L., Mitchell, R., and Gospodarowicz, D.  1987.  Bovine granulosa cells produce basic fibroblast growth factor.  Endocrinology 121:597-603.

Mitchell, R. L., Hanks, S. K., and Verma, I. M.  1987.  "Protooncogene fos:  An inducible multifaceted gene".  In:  Symposium on fundamental cancer research, Vol. 39, pp99-113.  University of Texas System Cancer Center.

Billestrup, N., Mitchell, R. L., Vale, W., and Verma, I. M.  1987.  "Growth hormone releasing factor induces c-fos expression in cultured primary pituitary cells".  Molecular Endocrinology 1:  300-305.

Van Beveren, C., Mitchell, R. L., Henning-Chubb, C., Huberman, E., and Verma, I. M.  1987.  "Expression of the c-fos gene during differentiation".  Adv. Exp. Med. Biol. 213:263-274.

Mitchell R. L., Henning-Chubb, C., Huberman, E., and Verma, I. M.  1987. "c-fos expression is neither sufficient nor obligatory for differentiation of monomyelocytes to macrophages".  Cell 45:497-504.

Verma, I. M., Mitchell, R. L., Sassone-Corsi, P.  1986.  Proto-oncogene fos:  an inducible gene.  Princess Takamatsu Symposium 17:279-290.

Mitchell, R. L., Kruijer, W., Schubert, D., Van Beveren, C., and Verma, I. M.. 1986.  "Structure and expression of protooncogene fos".  In:  Proceedings of the Seventh International Symposium on Host Defense Mechanisms Against Cancer.  Excerpta Medica, Tokyo.

Mitchell, R. L.  1986.  "Post development intensification of autoradiographs".  BRL Focus 8(3):10-11.

Coussens, L., Van Beveren, C., Smith, D., Chen, E., Mitchell, R. L., Isacke, C. M., Verma, I. M., and Ulrich, A. 1986.  "Molecular architecture of receptor proto-oncogene fms:  Structural alteration of viral homologue at carboxyl terminus".  Nature 320:  277-280.

Verma, I. M., Mitchell, R. L., Kruijer, W., Van Beveren, C., Zokas, L., Hunter, T., and Cooper, J. A.  1985.  "Protooncogene fos:  Induction and regulation during growth and differentiation.  Cancer Cells.  3:  Growth factors and transformation".  Feramisco, J., B. Ozanne, and C. Stiles, Eds.  Cold Spring Harbor Laboratory, New York.  pp 275-287.

Mitchell, R. L., Zokas, L., Schreiber, R. D., and Verma, I. M.. 1985.  "Rapid induction of the expression of proto-oncogene fos during human monocyte differentiation".  Cell 40:  209-217.

Deschamps, J., Mitchell, R. L., Meijlink, F., Kruijer, W., Schubert, D., and Verma, I. M.  1985.  "Proto-oncogene fos is expressed during development, differentiation, and growth".  Cold Spring Harbor Symposia on Quantitative Biology 50:  733-745.

Krzyzek, R. A., Mitchell, R. L., Lau, A. F., and Faras, A. J.  1980.  "Association of pp60src and src protein kinase activity with the plasma membrane of nonpermissive and permissive avian sarcoma virus-infected cells".  J. Virol. 36:  805-815.

Crouch, N.A., and Mitchell, R. L.  1978.  "Replication of vesicular stomatitis virus is facilitated by Shope fibroma virus in vivo".  Infect. Imm. 25:  213-219.

Lautermilchn N., Bishopn A., Marcoen K., Boundsn S., Linn C-H., Fengn J-J., Linn A., Chengn F-C., Mitchelln R., Chiun P., Baumgartnern J. 2005.  Comparison of a hERG Binding Assay with Automated Patch Clamp Using the PatchXpress 7000A.  Soc. Biolmol. Screening Ann. Mtg. P07036

Marcoe, K.F., Mitchell, R.L., Baumgartner, J.W.  Binding Affinity of Amyloidogenic, Inflammatory and Antimicrobial Immunogenic Peptide Ligands to the Formyl Peptide Receptor-Like 1.  2004. Soc Biomol. Screening Annual Mtg.

Shen, E., Mulligan, J., Castillo, G., Mitchell, R. 2004. FastKinaseTM for Rapid Determination of Multiple IC50 Profiles in a Panel of 24 Kinases.  Soc. Biol. Screening Ann. Mtg.

Bounds, S., Mitchell, R. 2004. Development of High Throughput Matrix Metalloproteinase Activity Assays.  Soc. Biolmol. Screening Ann. Mtg.

 P. Chiu, F-C. Cheng, A. Lin, K-K. Chang, R. Mitchell, N. Share, D. Menard. 2004.  An Integrated Approach to Screen for Anti-Diabetic Agents.  Soc. Biolmol. Screening Ann. Mtg.

Marcoe, K.F. and Mitchell, R.L. 2004.  A High Throughput Radioligand Binding Assay for the Leptin OB-Rb Receptor.  Soc. Biolmol. Screening Ann. Mtg.

Marcoe, K.F., Mitchell, R.L., Baumgartner, J.W. 2004. Binding affinity of amyloidogenic, inflammatory and antimicrobial immunogenic peptide ligands to the formyl peptide receptor-like 1. Soc. Biomol. Screening 10^th Annual Conference

Martel, L., Mulligan, J., Castillo, G., Mitchell, R., Baumgartner, J. 2004. Pharmacological characterization of Eph receptor tyrosine kinases with anti-angiogenic agent genistein.  Soc. Biomol. Screening 10^th Annual Conference.

Mulligan, J. Castillo, G., Mitchell. R.L. 2003. Characterization of Cathepsin Substrate and Inhibitor Specificities. Soc. Biol. Screening Ann. Mtg.

Gee, P., Mitchell, R., Browne, L., Kolaja, K., Jarnagin, K., Natsoulis, G., Roter, A. 2003. DrugMatrix™ provides predictive chemogenomics solutions for safety assessment in drug discovery and development. Eurotox 2003, Florence, Italy. Abstract 213.

Y. Lai, Mackie, K., Mitchell, R.  1994.  Cannabinoids activate an inwardly rectifying potassium conductance and inhibit a calcium current in AtT20 cells expressing rat cannabinoid receptor.  Can. J. Physiol. Pharmacol. 72 (Suppl. 1):423.

P. Hill, ,Y., Hnilo, J., Middlemas, D. S., Lin, C., Hsing, H., Leung, F., Karla, M., Bounds, S., Herz, J., Chen, C., Mitchell, R.  1994.  Comparison of binding characteristics of the known human dopamine receptors.  Can. J. Physiol. Pharmacol. 72 (Suppl. 1):383.

Mitchell, R.L., Hill, P., Lai, Y., Hnilo, J., Lin, C., Hsing, H., Leung, F., Karla, M., Bounds, S., Middlemas, D., Herz, J.  1994.  Cloning, expression, and comparison of the binding characteristics of the known human dopamine receptors.  11th International Symposium on Parkinson's Disease, Rome.

Mitchell, R.  1994.  Human U937 promonocytes express an alternatively spliced mRNA encoding a shortened isoform of cytosolic phospholipase A2.  FASEB J. 8(4):A217.

Middlemas, D. S., Hill, P., Lai, Y., Hnilo, J., Lin, C., Hsing, H., Leung, F., Karla, M., Bounds, S., Herz, J., Chen, C., and Mitchell, R.  1994.  Comparison of binding characteristics of the known human dopamine receptors.  FASEB J. 8(4):A106.

Lai, Y., Mackie, K., Mitchell, R.  1994.  Cannabinoids activate an inwardly rectifying potassium conductance in AtT20 cells expressing rat cannabinoid receptor.  FASEB J. 8(4):A381.

Hill, P. A., and Mitchell, R. L.  1994.  Characterization of phosphodiesterase activity from U937 cells.  FASEB J. 8(4):A217.

Bounds, S., Hill, P., and Mitchell, R.  1994.  Development of a glucocorticoid receptor transcription response element (GTRE) assay.  FASEB J. 8(5):A650.

Hnilo, J. M., Mitchell, R. L., Hill, P. A., Crawford, M. S.  1991.  Development of functional tyrosine kinase assays based on EGF and PDGF receptor cytoplasmic domains expressed in Sf9 insect cells.  The Pharmacologist 33:174.

Mitchell, R. L., Hnilo, J. M., Maechler, L., Crawford, M. S.  1991.  Development of functional tyrosine kinase assays based on EGF and PDGF receptor cytoplasmic domains expressed in Sf9 insect cells.  Sixth S.E. Asia/W. Pacific Regional Mtg. of Pharmacologists.

Hnilo, J. M., Mitchell, R. L., Maechler, L., Crawford, M. S.  1991.  Development of a functional tyrosine kinase assay based on EGF receptor tyrosine kinase domain expressed in Sf9 insect cells.  Soc. Indus. Microbiol. Ann. Mtg., 1991.

Mitchell, R. L., Silver, S., Abraham, J. A., Fiddes, J. C.  1988.  CHO cells transfected with basic fibroblast growth factor linked to growth hormone secretion signal efficiently secrete 18 kD FGF and several modified forms of the protein.  NCI-FCRF Fourth Ann. Mtg. On Oncogenes p429.

Blam, S. B., Mitchell, R., Tischer, E., Rubin, J. S., Silva, M., Silver, S., Fiddes, J. C., Abraham, J. A., Aaronson, S. A. 1988.  Addition of growth hormone secretion signal to basic fibroblast growth factor results in cell transformation and secretion of aberrant forms of the protein.  NCI-FCRF Fourth Ann. Mtg. on Oncogenes p24.

Mitchell, R. L., Henning-Chubb, C., Huberman, E., and Verma, I. M.  1987.  c-fos expression is neither sufficient nor obligatory for differentiation of monomyelocytes to macrophages.  In:  1987 Year Book of Cancer, Year Book Medical Publishers, Houston.

Mitchell, R. L., Hanks, S. K., Henning-Chubb, C., Huberman, E., and Verma, I. M. 1986.  Role of the protooncogene fos during growth and differentiation.  NCI-FCRF Second Ann. Mtg. On Oncogenes.

Mitchell, R. L., and Verma, I. M.  1985.  Expression of the protooncogenes c-fos and c-fms during hematopoietic differentiation.  NCI-FCRF First Annual Mtg. on Oncogenes.

Lau, A., Faras, A., Mitchell, R., and Collins, C.  1981.  ASV transformed and revertant field vole cells:  pp60src, cellular protein substrates, and arrangement of the integrated ASV genome.  1991 Ann. Mtg. on RNA Tumor Viruses.  Cold Spring Harbor Laboratories.

Crouch, N. A., and Mitchell, R. L. 1978.  Facilitative effect of Shope fibroma virus on the replication of vescicular stomatitis virus in vivo.  Abs. of the 78th Ann. Mtg. of the Am. Soc. Microbiol.

TIDES 2008, Las Vegas, NV.  Update on Intranasal Insulin Clinical Trials: Ideal Pharmacokinetics for Prandial Insulin in Type 2 Diabetics. (May 2008).

Natural Peptides to Drugs - International Congress, Zermatt, Switzerland. Invited Plenary Lecture. (April 14-18, 2008).

American Society for Pharmacology and Experimental Therapeutics 2008. (ASPET): Role of Oxytocin in Autistic Spectrum Disorder, and the Development of Intranasal Carbetocin as a Potential Therapeutic for Autism and Asperger's. Invited speaker. (March 2008).

Drug Delivery Partnerships. San Diego, CA.  How to Pursue and Assess Potential Technologies as Synergistic Fits for Your Program. Invited panelist. (January 21, 2008).

Invited Speaker, 3rd Annual Metabolic Diseases World Summit, San Diego, CA Intranasal Delivery Of Insulin Exhibits Pharmacokinetic Advantages for the Prandial Delivery of Insulin in Human Clinical Trials. (November 1-2, 2007).

Invited Speaker, Drug Delivery 2007, San Diego, CA. Update on Clinical Development of Intranasal Peptide Therapeutics: Results from Phase 1 Clinical Trials with Intranasal Insulin. (June 6-8, 2007).

Drug Delivery Partnerships, Las Vegas, NV. Intranasal drug delivery: challenges and solutions through formulations and drug devices. (January 24, 2007).

EuroTIDES, Hamburg, Germany. Development of a non-invasive intranasal insulin, an alternative to injectable insulin (December 6, 2006).